Osteoarthritis Drugs Market to Reach a Value of About US$ 11,226.1 Mn by the End of 2026
Read Report Overview: https://www.transparencymarketresearch.com/osteoarthritis-drugs-market.html
According to the Arthritis Foundation, 130 million individuals around the globe are expected to be affected by osteoarthritis by 2050. Geriatric population and high prevalence of obesity are likely to continue to contribute to the increasing prevalence of osteoarthritis, placing a major burden on individuals, health systems, and social care systems across the world. Rise in incidence of osteoarthritis is expected to boost the demand for improved drugs and new therapies. Obesity is considered a risk factor for osteoarthritis, especially knee osteoarthritis. According to the World Health Organization, the prevalence of obesity has nearly tripled since 1975, globally. In 2016, more than 650 million adults and 41 million children, under the age of five, were obese.
Osteoarthritis (OA) is the most common arthritis condition and is a major cause of impaired mobility and disability among people. Currently available treatment options are insufficient, as they primarily focus on symptoms relief and pain mitigation. There are no drugs available that can cure, reverse, or halt disease progression. Several patients are unable to find relief through the currently available medicines and continue to suffer in pain; therefore, there is high need for innovative treatment options for osteoarthritis. However, high cost of viscosupplementation and increasing competition from generic drugs are restraining the market. Furthermore, withdrawal of opioids has also negatively affected the market share of various companies, globally, owing to abuse of opioids as a pain reliever.
The osteoarthritis drugs market has been segmented based on drug class, route of administration, distribution channel, and region. Based on drug class, the market has been classified into corticosteroids, NSAIDs & others, and viscosupplementation agents. Viscosupplementation agents consist of hyaluronic injections available in five, three, and single form of injections and is completely utilized to manage osteoarthritis. Rise in demand for viscosupplementation agents is due to their effective and rapid pain relieving property. The viscosupplementation agents segment accounted for a higher share of the market, in terms of value, than NSAIDs and corticosteroids segments. It is likely to expand at a rapid pace in the near future.
Perceive the Sample of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=47571
North America is expected to lead the global osteoarthritis drugs market, and account for a significant share, by the end of 2026. Increasing prevalence of osteoarthritis in patients, rising healthcare expenditure, increasing investments, and high preference for viscosupplementation over traditional medication are key factors that are anticipated to boost the global osteoarthritis drugs market in the next few years. Innovative therapy and upcoming product launches in North America are expected to propel the osteoarthritis drugs market in the region, followed by Asia Pacific, and Europe. Few companies are investing to expand their footprint in the U.S. by launching viscosupplementation products.
ANTI-NGF, known as anti-nerve growth factor, is a unique upcoming therapy for osteoarthritis. Anti-nerve growth factor with antibodies is a promising way to treat the chronic pain associated with osteoarthritis. Strong pipeline investments is a major opportunity for the global osteoarthritis drugs market. Disease modifying osteoarthritis drug (DMOAD) is seen as an opportunity for companies to strengthen their portfolio and enhance their presence in the osteoarthritis drug market. This drug improves the joints function and inhibits the structural disease progression. No DMAOD has been licensed till date, worldwide; therefore, companies investing in this therapy have the chance to create a growth wave in the osteoarthritis drugs market. Development of disease modifying therapies offers considerable market opportunities for osteoarthritis drugs. Nanobody is another promising therapy to treat osteoarthritis disease. All these upcoming novel therapies are seeking to bring a chance of providing effective treatment to the patients.
Key players dominating the global osteoarthritis drug markets are Horizon Pharma plc, Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Inc, Chugai Pharmaceutical Co., Limited, Alkem Laboratories, Flexion Therapeutics, Inc., and Zimmer Biomet Holdings, Inc.
Obtain the Brochure of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=47571
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Transparency Market Research
90 Sate Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Osteoarthritis Drugs Market to Reach a Value of About US$ 11,226.1 Mn by the End of 2026 here
News-ID: 1562183 • Views: 182
More Releases from Transparency Market Research
Powder Coatings Market to Reach US$ 16,203.14 Mn by 2026 Need for Increased Agri …
The demand within the global powder coatings market is slated to grow by leaps and bounds in the years to follow. The need for coating several materials and products with protective layers has played a vital role in the growth of the global powder coatings market. Request Overview - https://www.transparencymarketresearch.com/powder-coatings-market.html Furthermore, advancements in organic as well as polymer chemistry have paved way for key developments within the market. Several industrial manufacturers acknowledge
Fumigation Products Market to Reach a Value of US$ 1.2 Bn by 2027-Lack of Awaren …
Fumigation Products Market: Key Highlights The global fumigation products market was valued at ~US$ 820 Mn in 2018, and is anticipated to expand at a CAGR of ~4% during the forecast period. The global fumigation products market is driven by the rise in the demand for warehouses/storage and residential applications North America accounts for a major share of the global fumigation products market, led by an increase in the demand for residential housing,
Inks Market will Generate Revenue of US$ 21.2 Bn by 2027- Technological Advancem …
Global Inks Market: Key Highlights The global inks market was valued at ~US$ 15.9 Bn in 2018, and is anticipated to expand at a CAGR of ~3% from 2019 to 2027. Rise in population and urbanization is fueling global trade, and subsequently, the use of packaging. Online trade is further increasing the need for packaging. Products are also being consumed immediately, which is driving the need for food service packaging and
Zinc-Bromine Battery Market to Reach Value US$ 23 Mn by 2027 Enhancing Storage i …
The global zinc-bromine battery market was valued at ~US$ 5 Mn in 2018, and is anticipated to expand at a CAGR of ~18% from 2019 to 2027, according to a new research report published by Transparency Market Research (TMR). Increase in the demand for zinc-bromine batteries in power distribution applications is one of the major factors driving the zinc-bromine battery market. In terms of consumption, Asia Pacific accounted for a
More Releases for Osteoarthritis
Osteoarthritis Treatment Market by Product (Drugs, Hyaluronic acid Injection) by …
Global Osteoarthritis Treatment Market was valued at USD XX Billion in the year 2017. Global Osteoarthritis Treatment Market is further estimated to grow at a CAGR of XX % from 2018 to reach USD XX Billion by the year 2023. Get Free Access to Sample Report @ https://genesismarketinsights.com/Sample_Request/GENRE369 North America region holds the highest market share in 2017 and is considered as the fastest growing market in the forecasted period. At a
Osteoarthritis-Pipeline Review H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis-Pipeline Review, H2 2017, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape. Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint
Osteoarthritis Global Clinical Trials Review, H1, 2016
ReportsWeb.com published “Osteoarthritis” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. GET Sample Copy at http://www.reportsweb.com/inquiry&RW0001178647/sample Reason to Buy Original Content: - The UK and the EU will be at the forefront of moves to practically apply the principles of open banking in 2017, spurred on by regulatory demands. The
Osteoarthritis - Pipeline Review, H2 2017
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H2 2017, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape. Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older
Osteoarthritis - Pipeline Review, H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H1 2017, provides an overview of the Osteoarthritis (Immunology) pipeline landscape. Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries
Osteoarthritis Pharmaceutical and Healthcare Pipeline Review H2
Pune, India, 28th August 2017: WiseGuyReports announced addition of new report, titled “Osteoarthritis - Pipeline Review, H2 2017”. Summary Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery,